Pharsight

Impoyz is owned by Primus Pharms.

Impoyz contains Clobetasol Propionate.

Impoyz has a total of 4 drug patents out of which 0 drug patents have expired.

Impoyz was authorised for market use on 28 November, 2017.

Impoyz is available in cream;topical dosage forms.

Impoyz can be used as treatment of moderate plaque psoriasis; treatment of plaque psoriasis; psoriasis; treatment of plaque psoriasis in patients 18 years of age or older; twice daily topical treatment of moderate to severe plaque psoriasis., treatment of moderate plaque psoriasis; treatment of plaque psoriasis in patients 18 years of age or older; psoriasis; twice daily topical treatment of moderate to severe plaque psoriasis.; treatment of plaque psoriasis; plaque psoriasis, treatment of moderate to severe plaque psoriasis in patients 18 years of age or older.

The generics of Impoyz are possible to be released after 11 March, 2035.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10064875	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (7 years from now)
US9956231	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (7 years from now)
US10588914	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (7 years from now)
US9855334	PRIMUS PHARMS	Topical compositions comprising a corticosteroid	Mar, 2035 (12 years from now)

Drugs and Companies using CLOBETASOL PROPIONATE ingredient

Market Authorisation Date: 28 November, 2017

Treatment: Treatment of moderate plaque psoriasis; Treatment of plaque psoriasis; Psoriasis; Treatment of plaque psoriasis in patients 18 years of age or older; Twice daily topical treatment of moderate to severe plaque psoriasis.; Plaque psoriasis; Treatment of moderate to severe plaque psoriasis in patients 18 years of age or older

Dosage: CREAM;TOPICAL